<DOC>
	<DOCNO>NCT01505946</DOCNO>
	<brief_summary>This observational , prospective , longitudinal , multicenter , cohort study design scope verify whether TGA may predict effectiveness different FVIII concentrate class ( devoid rich VWF ) patient affect severe moderately severe inherit haemophilia A inhibitor .</brief_summary>
	<brief_title>Thrombin Generation Assay ( TGA ) Predictive Test Haemostatic . Effectiveness FVIII Concentrates Haemophiliac A With Inhibitors</brief_title>
	<detailed_description>Rationale : Hemophilia A serious common hereditary bleeding disorder cause deficiency coagulation factor VIII ( FVIII ) . Patients disease treat recombinant factor VIII factor VIII concentrate derive plasma . Administration exogenous FVIII 15-35 % case , cause formation antibody FVIII ( inhibitor ) neutralize activity factor VIII , make treatment ineffective.The development inhibitor factor VIII ( FVIII ) serious challenge complication treatment hemophilia A represent high economic burden chronic disease . Therefore , research make great effort optimize best therapeutic approach disease . It observe FVIII inhibitor display wide range immunoreactivity test different class FVIII concentrate ( with/without von Willebrand factor -VWF ) . It demonstrate different inhibitor reactivity may correlate different ability inhibitor impair thrombin generation , test Thrombin Generation Assay ( TGA ) . In patient TGA assay might tool predict FVIII concentrate great haemostatic effectiveness . It also uncertain different class FVIII use ITI protocol may different effectiveness reduce occurrence BT bleeding may correlate low reactivity , epitope specificity , VWF content may predict TGA . It would helpful able give evidence base diagnostic prognostic instrument , TGA , aid physician optimize therapy inhibitor patient .</detailed_description>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Thrombin</mesh_term>
	<mesh_term>Hemostatics</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Diagnosis inherit , severe ( FVIII : C &lt; 1 % ) moderately severe haemophilia A ( FVIII ≤ 2 % ) Any age Ability comply study method willingness participate study Written inform consent . FOR THE LOW RESPONDERS COHORT Documented low anamnestic response FVIII exposure ( FVIII inhibitor titre &gt; 0.6 &lt; 5 BU/ml test Bethesda assay , Nijmegen modification ) . It include study patient never submit ITI also patient complete ITI partial success ( defined inhibitor titre &gt; 0.6 &lt; 5 BU/ml increase INH titer &gt; 5 BU treatment FVIII ) INCLUSION CRITERIA FOR THE HIGH RESPONDERS COHORT Documented high response FVIII exposure ( FVIII inhibitor titre &gt; 5 BU/ml test Bethesda assay , Nijmegen modification ) . It include study patient potential candidate first rescue ITI . Any historical peak ≥ 5 BU Diagnosis acquire haemophilia Diagnosis inherit mild haemophilia A ( FVIII &gt; 2 % ) Life expectancy lower 1 year Psychiatric illness condition may impair ability comply study method</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Thrombin</keyword>
	<keyword>Hemophilia</keyword>
	<keyword>Inhibitors</keyword>
	<keyword>Immunotolerance</keyword>
	<keyword>Haemostatic</keyword>
	<keyword>FVIII</keyword>
	<keyword>Epitopes</keyword>
	<keyword>Moderately severe Hemophilia A inhibitor</keyword>
</DOC>